Veru Inc. (NASDAQ: VERU) reported its financial results for the quarter ended March 31, 2020, on Wednesday before the market opens. The company posted a narrower loss for Q2 as the substantial growth in prescription sales of FC2 drove the top-line higher.
On Tuesday, Veru received FDA permission to initiate a phase 2 clinical trial to assess the efficacy of VERU-111 in combating COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2. Veru has initiated the study and expects the first patient to be dosed within 2 weeks.
The company believes that VERU-111, a microtubule depolymerization agent that has broad antiviral activity, could be effective against the SARS CoV-2 virus by disrupting its intracellular transport along the microtubules. Microtubule trafficking is critical for viruses to cause infection.
Past Performance
Most Popular
Important takeaways from Conagra Brands’ Q4 2025 report
Conagra Brands, Inc. (NYSE: CAG), a leading provider of consumer packaged goods, reported weaker-than-expected sales and adjusted earnings for its fourth quarter, reflecting ongoing economic uncertainty and muted consumer spending.
Delta Air Lines (DAL) gains on strong Q2 2025 performance
Shares of Delta Air Lines (NYSE: DAL) rose 12% on Thursday after the company delivered strong results for the second quarter of 2025 and restored its guidance for the full
CAG Earnings: Conagra Brands Q4 adj. profit drops, misses estimates
Conagra Brands, Inc. (NYSE: CAG), a leading provider of consumer packaged goods, reported lower sales and adjusted earnings for the fourth quarter of 2025. Results missed analysts' estimates. Net sales
